mBio (Aug 2022)

The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia

  • Chuangqi Wang,
  • Yijia Li,
  • Paulina Kaplonek,
  • Matteo Gentili,
  • Stephanie Fischinger,
  • Kathryn A. Bowman,
  • Moshe Sade-Feldman,
  • Kyle R. Kays,
  • James Regan,
  • James P. Flynn,
  • Marcia B. Goldberg,
  • Nir Hacohen,
  • Michael R. Filbin,
  • Douglas A. Lauffenburger,
  • Galit Alter,
  • Jonathan Z. Li

DOI
https://doi.org/10.1128/mbio.01577-22
Journal volume & issue
Vol. 13, no. 4

Abstract

Read online

ABSTRACT Persistent SARS-CoV-2 replication and systemic dissemination are linked to increased COVID-19 disease severity and mortality. However, the precise immune profiles that track with enhanced viral clearance, particularly from systemic RNAemia, remain incompletely defined. To define whether antibody characteristics, specificities, or functions that emerge during natural infection are linked to accelerated containment of viral replication, we examined the relationship of SARS-CoV-2-specific humoral immune evolution in the setting of SARS-CoV-2 plasma RNAemia, which is tightly associated with disease severity and death. On presentation to the emergency department, S-specific IgG3, IgA1, and Fc-γ-receptor (Fcγ R) binding antibodies were all inversely associated with higher baseline plasma RNAemia. Importantly, the rapid development of spike (S) and its subunit (S1/S2/receptor binding domain)-specific IgG, especially FcγR binding activity, were associated with clearance of RNAemia. These results point to a potentially critical and direct role for SARS-CoV-2-specific humoral immune clearance on viral dissemination, persistence, and disease outcome, providing novel insights for the development of more effective therapeutics to resolve COVID-19. IMPORTANCE We showed that persistent SARS-CoV-2 RNAemia is an independent predictor of severe COVID-19. We observed that SARS-CoV-2-targeted antibody maturation, specifically Fc-effector functions rather than neutralization, was strongly linked with the ability to rapidly clear viremia. This highlights the critical role of key humoral features in preventing viral dissemination or accelerating viremia clearance and provides insights for the design of next-generation monoclonal therapeutics. The main key points will be that (i) persistent SARS-CoV-2 plasma RNAemia independently predicts severe COVID-19 and (ii) specific humoral immune functions play a critical role in halting viral dissemination and controlling COVID-19 disease progression.

Keywords